enGene Holdings Inc. (ENGN), which reported promising initial efficacy and safety data from the pivotal cohort of its LEGEND trial of Detalimogene voraplasmid last year, is expected to provide an update this quarter.
Detalimogene is a novel, investigational, non-viral gene-based immunotherapy for patients with high-risk non-muscle-invasive bladder cancer, including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumour immune response.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com